Format

Send to

Choose Destination
Diagn Microbiol Infect Dis. 2017 Mar;87(3):213-218. doi: 10.1016/j.diagmicrobio.2016.09.001. Epub 2016 Sep 8.

Validation of IgG, IgM multiplex plasmonic gold platform in French clinical cohorts for the serodiagnosis and follow-up of Toxoplasma gondii infection.

Author information

1
Division of Infectious Diseases, Stanford University, Stanford, California 94305, USA; Palo Alto Medical Foundation Toxoplasma Serology Laboratory, Palo Alto, California, USA; INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la Relation Hôte Pathogènes - Université de Nice Sophia Antipolis, Faculté de Médecine, 06204 Nice, Cedex 3, France; Parasitologie-Mycologie, Centre Hospitalier Universitaire l'Archet, CS 23079, 06202 Nice, Cedex 3, France. Electronic address: pomares.c@chu-nice.fr.
2
Nirmidas Biotech Inc., Palto Alto, CA 94304, USA. Electronic address: bo.zhang@nirmidas.com.
3
Nirmidas Biotech Inc., Palto Alto, CA 94304, USA.
4
Virologie, Centre Hospitalier Universitaire l'Archet, CS 23079, 06202 Nice, Cedex 3, France.
5
INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la Relation Hôte Pathogènes - Université de Nice Sophia Antipolis, Faculté de Médecine, 06204 Nice, Cedex 3, France; Parasitologie-Mycologie, Centre Hospitalier Universitaire l'Archet, CS 23079, 06202 Nice, Cedex 3, France.
6
Department of Chemistry, Stanford University, CA 94305, USA.
7
Division of Infectious Diseases, Stanford University, Stanford, California 94305, USA; Palo Alto Medical Foundation Toxoplasma Serology Laboratory, Palo Alto, California, USA.

Abstract

We report the use of the multiplexed T. gondii IgG, IgM test on plasmonic gold (pGOLD) platform in the setting of T. gondii infection by analyzing 244 sera from Nice, France (seroconversion, chronically infected, non-infected and newborns serum samples). Results were compared with commercial tests for the detection of IgG and IgM and their overall clinical final interpretation of a complete serological profile. The IgG and IgM test results on the platform were in agreement in, respectively, 95% and 93% with the commercial kits. When comparing with the overall clinical interpretation of the serological profile, the agreement reached 99.5% and 97.7% for IgG and IgM, respectively. This innovative pGOLD platform allows detection of both IgG and IgM simultaneously with only ~1 microliter of serum. The multiplexed IgG/IgM test on pGOLD platform is a strong candidate for its use in the massive screening programs for toxoplasmosis during pregnancy.

KEYWORDS:

Adults; Multiplex serology; Newborns; Plasmonic gold pGOLD; Seroconversion; Toxoplasma gondii

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center